Cargando…

Medicaid spending on contraceptive coverage and pregnancy-related care

OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including uni...

Descripción completa

Detalles Bibliográficos
Autores principales: Laliberté, François, Lefebvre, Patrick, Law, Amy, Duh, Mei Sheng, Pocoski, Jennifer, Lynen, Richard, Darney, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946128/
https://www.ncbi.nlm.nih.gov/pubmed/24581033
http://dx.doi.org/10.1186/1742-4755-11-20
_version_ 1782306612042530816
author Laliberté, François
Lefebvre, Patrick
Law, Amy
Duh, Mei Sheng
Pocoski, Jennifer
Lynen, Richard
Darney, Philip
author_facet Laliberté, François
Lefebvre, Patrick
Law, Amy
Duh, Mei Sheng
Pocoski, Jennifer
Lynen, Richard
Darney, Philip
author_sort Laliberté, François
collection PubMed
description OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including unintended pregnancies. METHODS: We analyzed Medicaid health claims data from 2004 to 2010. Women 14–49 years of age initiating contraceptive methods and pregnant women were included as separate cohorts. Medicaid spending was summarized using mean all-cause and contraceptive healthcare payments per patient per month (PPPM) over a follow-up period of up to 12 months. Medicaid payments were also estimated in 2008 per female member of childbearing age per month (PFCPM) and per member per month (PMPM). Medicaid payments on unintended pregnancies were also evaluated PFCPM and PMPM in 2008. RESULTS: For short-acting reversible contraception (SARC) users, all-cause payments and contraceptive payments PPPM were respectively $365 and $18.3 for oral contraceptive (OC) users, $308 and $19.9 for transdermal users, $215 and $21.6 for vaginal ring users, and $410 and $8.8 for injectable users. For long-acting reversible contraception (LARC) users (follow-up of 9–10 months), corresponding payments were $194 and $36.8 for IUD users, and $237 and $29.9 for implant users. Pregnancy cohort all-cause mean healthcare payments PPPM were $610. Payments PFCPM and PMPM for contraceptives were $1.44 and $0.54, while corresponding costs of pregnancies were estimated at $39.91 and $14.81, respectively. Payments PFCPM and PMPM for contraceptives represented a small fraction at 6.56% ($1.44/$21.95) and 6.63% ($0.54/$8.15), respectively of the estimated payments for unintended pregnancy. CONCLUSIONS: This study of a large sample of Medicaid beneficiaries demonstrated that, over a follow-up period of 12 months, Medicaid payments for pregnancy were considerably higher than payments for either SARC or LARC users. Healthcare payments for contraceptives represented a small proportion of payments for unintended pregnancy when considering the overall Medicaid population perspective in 2008.
format Online
Article
Text
id pubmed-3946128
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39461282014-03-09 Medicaid spending on contraceptive coverage and pregnancy-related care Laliberté, François Lefebvre, Patrick Law, Amy Duh, Mei Sheng Pocoski, Jennifer Lynen, Richard Darney, Philip Reprod Health Research OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including unintended pregnancies. METHODS: We analyzed Medicaid health claims data from 2004 to 2010. Women 14–49 years of age initiating contraceptive methods and pregnant women were included as separate cohorts. Medicaid spending was summarized using mean all-cause and contraceptive healthcare payments per patient per month (PPPM) over a follow-up period of up to 12 months. Medicaid payments were also estimated in 2008 per female member of childbearing age per month (PFCPM) and per member per month (PMPM). Medicaid payments on unintended pregnancies were also evaluated PFCPM and PMPM in 2008. RESULTS: For short-acting reversible contraception (SARC) users, all-cause payments and contraceptive payments PPPM were respectively $365 and $18.3 for oral contraceptive (OC) users, $308 and $19.9 for transdermal users, $215 and $21.6 for vaginal ring users, and $410 and $8.8 for injectable users. For long-acting reversible contraception (LARC) users (follow-up of 9–10 months), corresponding payments were $194 and $36.8 for IUD users, and $237 and $29.9 for implant users. Pregnancy cohort all-cause mean healthcare payments PPPM were $610. Payments PFCPM and PMPM for contraceptives were $1.44 and $0.54, while corresponding costs of pregnancies were estimated at $39.91 and $14.81, respectively. Payments PFCPM and PMPM for contraceptives represented a small fraction at 6.56% ($1.44/$21.95) and 6.63% ($0.54/$8.15), respectively of the estimated payments for unintended pregnancy. CONCLUSIONS: This study of a large sample of Medicaid beneficiaries demonstrated that, over a follow-up period of 12 months, Medicaid payments for pregnancy were considerably higher than payments for either SARC or LARC users. Healthcare payments for contraceptives represented a small proportion of payments for unintended pregnancy when considering the overall Medicaid population perspective in 2008. BioMed Central 2014-03-03 /pmc/articles/PMC3946128/ /pubmed/24581033 http://dx.doi.org/10.1186/1742-4755-11-20 Text en Copyright © 2014 Laliberté et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Laliberté, François
Lefebvre, Patrick
Law, Amy
Duh, Mei Sheng
Pocoski, Jennifer
Lynen, Richard
Darney, Philip
Medicaid spending on contraceptive coverage and pregnancy-related care
title Medicaid spending on contraceptive coverage and pregnancy-related care
title_full Medicaid spending on contraceptive coverage and pregnancy-related care
title_fullStr Medicaid spending on contraceptive coverage and pregnancy-related care
title_full_unstemmed Medicaid spending on contraceptive coverage and pregnancy-related care
title_short Medicaid spending on contraceptive coverage and pregnancy-related care
title_sort medicaid spending on contraceptive coverage and pregnancy-related care
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946128/
https://www.ncbi.nlm.nih.gov/pubmed/24581033
http://dx.doi.org/10.1186/1742-4755-11-20
work_keys_str_mv AT lalibertefrancois medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT lefebvrepatrick medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT lawamy medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT duhmeisheng medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT pocoskijennifer medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT lynenrichard medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare
AT darneyphilip medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare